Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol Unveils Post-Celgene Leadership Team, With Big R&D Changes

Jun 05 2019

• By Jessica Merrill

merger and acquisition business concepts, join company on puzzle pieces, 3d rendering

Related Content

Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?

Jan 04 2019

Novartis' New Oncology CEO Schaffert Has A Potential Blockbuster Launch On Her Hands

May 23 2019

As Expected: Shareholders Back Bristol's $74bn Celgene Buy

Apr 12 2019

Related Companies

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Novartis AG

Bristol Myers Squibb Company

Additional Topics

Leadership Deals Business Strategies Commercial BioPharmaceutical

More from Leadership

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.